TheEdgeResearch
Home / Stocks / BVS

Bioventus Inc. (BVS)

NASDAQ Healthcare Medical - Devices
$13.56 ▼ -2.09%
Market Cap
$918.7M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.65
52-Wk Range
6.255-15.893
CEO
Robert Claypoole
Country
US
Currency
USD

Bioventus Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Durham, NC, US. The stock last traded at $13.56, down 2.09% on the session, giving a market capitalisation of $918.7M. On trailing twelve-month figures it carries a trailing P/E of 16.88, a net margin of 9.4%. Its beta of 0.65 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
16.88
Price / Sales
1.58
Price / Book
4.03
EV / EBITDA
12.42
Gross margin
68.0%
Operating margin
10.6%
Net margin
9.4%
Return on equity
Debt / equity
1.16
Current ratio
1.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
950
IPO date
2021-02-11
Headquarters
Durham, NC, US
About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Comparable companies

Bioventus Inc. is most often compared with the following Healthcare names:

AVNSBFLYCBLLCTKBKIDSLABSMLRSRDXTMCIVREX
More research on BVS
BVS technical analysis BVS TheEdge Score Compare against peers
Open full interactive analysis & DCF →